SEC Comment Letter 0000000000-24-013329 to ALUMIS INC. (ALMS)
ALUMIS INC.
Date: Dec. 3, 2024 · CIK: 0001847367 · Accession: 0000000000-24-013329
AI Filing Summary & Sentiment
Reasoning
Letter
December 3, 2024 Srinivas Akkaraju Reporting Person Samsara BioCapital GP, LLC 628 Middlefield Road Palo Alto, CA 94301 Re:Samsara BioCapital GP, LLC Alumis Inc. Schedule 13D by Samsara BioCapital, L.P.; Samsara BioCapital GP, LLC; and Srinivas Akkaraju Filed August 27, 2024 File No. 005-94550 Dear Srinivas Akkaraju: We have conducted a limited review of the above-captioned filing and have the following comment. Please respond to this letter by amending the filing or by providing the requested information. If you do not believe our comment applies to your facts and circumstances or that an amendment is appropriate , please advise us why in a response letter. After reviewing any amendment to the filing and any information provided in response to this comment, we may have additional comments. Schedule 13D Filed August 27, 2024 General 1.We note that the event reported as requiring the filing of the Schedule 13D was July 1, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within five business days after the date beneficial ownership of more than five percent of a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the July 1, 2024 event date, the Schedule 13D submitted on August 27, 2024 was not timely filed. Please advise us why the Schedule 13D was not filed within the required five business days after the date of the acquisition. We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by
December 3, 2024 Page 2 the staff. Please direct any questions to Brian Soares at 202-551-3690 or Nicholas Panos at 202-551-3266. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
December 3, 2024
Srinivas Akkaraju
Reporting Person
Samsara BioCapital GP, LLC
628 Middlefield Road
Palo Alto, CA 94301
Re:Samsara BioCapital GP, LLC
Alumis Inc.
Schedule 13D by Samsara BioCapital, L.P.; Samsara BioCapital GP, LLC; and
Srinivas Akkaraju
Filed August 27, 2024
File No. 005-94550
Dear Srinivas Akkaraju:
We have conducted a limited review of the above-captioned filing and have the
following comment.
Please respond to this letter by amending the filing or by providing the requested
information. If you do not believe our comment applies to your facts and circumstances or
that an amendment is appropriate , please advise us why in a response letter.
After reviewing any amendment to the filing and any information provided in
response to this comment, we may have additional comments.
Schedule 13D Filed August 27, 2024
General
1.We note that the event reported as requiring the filing of the Schedule 13D was July 1,
2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within
five business days after the date beneficial ownership of more than five percent of a
class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the July
1, 2024 event date, the Schedule 13D submitted on August 27, 2024 was not timely
filed. Please advise us why the Schedule 13D was not filed within the required five
business days after the date of the acquisition.
We remind you that the filing persons are responsible for the accuracy and adequacy
of their disclosures, notwithstanding any review, comments, action or absence of action by
December 3, 2024
Page 2
the staff.
Please direct any questions to Brian Soares at 202-551-3690 or Nicholas Panos at
202-551-3266.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions